Though seldom previous research explored the clinical implications of concomitant mutations from multiple pathways in HER2-related signaling network for breast cancer, several previous studies [21–25] in EGFR-mutant advanced non-small cell lung cancer investigated the relationship between concomitant genetic alterations and survival outcomes. Here, ERBB2 is linked to breast carcinoma.